Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohns Disease

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Sena, Angela ^a,b   Grishina, Irina ^a   Thai, Anne ^c   Goulart, Larissa ^a   Macal, Monica ^a   Fenton, Anne ^a   Li, Jay ^a   Prindiville, Thomas ^c   Oliani, Sonia Maria ^d   Dandekar, Satya ^a   Goulart, Luiz ^a,b   Sankaran Walters, Sumathi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BACTERIAL DNA; DNA 16S; INFLIXIMAB; LIPOCORTIN 1; MERCAPTOPURINE; MESALAZINE; MESSENGER RNA; METHOTREXATE; STEROID; TACROLIMUS; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE MUCOSA; LONGITUDINAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERMEABILITY BARRIER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; ANNEXIN A1; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DISEASE PROGRESSION; DNA, BACTERIAL; DNA, RIBOSOMAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RNA, MESSENGER; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84885408176     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076969     Document Type: Article

References (53)

1. Abraham C, Medzhitov R, (2011) Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140: 1729-1737. doi:10.1053/j.gastro.2011.02.012. PubMed: 21530739.
2. Shih DQ, Targan SR, McGovern D, (2008) Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 10: 568-575. doi:10.1007/s11894-008-0104-x. PubMed: 19006613.
3. Xavier RJ, Podolsky DK, (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434. doi:10.1038/nature06005. PubMed: 17653185.
4. Macfarlane S, Steed H, Macfarlane GT, (2009) Intestinal bacteria and inflammatory bowel disease. Crit Rev Clin Lab Sci 46: 25-54. doi:10.1080/10408360802485792. PubMed: 19107650.
5. Siegmund B, Zeitz M, (2011) Innate and adaptive immunity in inflammatory bowel disease. World J Gastroenterol 17: 3178-3183. PubMed: 21912465.
6. Rakoff-Nahoum S, Bousvaros A, (2010) Innate and adaptive immune connections in inflammatory bowel diseases. Curr Opin Gastroenterol 26: 572-577. doi:10.1097/MOG.0b013e32833f126d. PubMed: 20871398.
7. Musch MW, Clarke LL, Mamah D, Gawenis LR, Zhang Z, et al. (2002) T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase. J Clin Invest 110: 1739-1747. doi:10.1172/JCI200215695. PubMed: 12464679.
8. Arijs I, Quintens R, Van Lommel L, Van Steen K, De Hertogh G, et al. (2010) Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 16: 2090-2098. doi:10.1002/ibd.21301. PubMed: 20848504.
9. Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, et al. (2010) New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis 16: 1239-1246. doi:10.1002/ibd.21212. PubMed: 20127998.
10. Meuwis MA, Fillet M, Lutteri L, Marée R, Geurts P, et al. (2008) Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem 41: 960-967. doi:10.1016/j.clinbiochem.2008.04.021. PubMed: 18489908.
11. Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, et al. (2011) Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol 50: 31-36. doi:10.1016/j.jcv.2010.09.011. PubMed: 21035384.
12. Cirino G, Flower RJ, Browning JL, Sinclair LK, Pepinsky RB, (1987) Recombinant human lipocortin 1 inhibits thromboxane release from guinea-pig isolated perfused lung. Nature 328: 270-272. doi:10.1038/328270a0. PubMed: 2955229.
13. Cirino G, Flower RJ, (1987) Human recombinant lipocortin 1 inhibits prostacyclin production by human umbilical artery in vitro. Prostaglandins 34: 59-62. PubMed: 2961007.
14. Perretti M, Dalli J, (2009) Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics. Br J Pharmacol 158: 936-946. doi:10.1111/j.1476-5381.2009.00483.x. PubMed: 19845684.
15. Oliani SM, Paul-Clark MJ, Christian HC, Flower RJ, Perretti M, (2001) Neutrophil interaction with inflamed postcapillary venule endothelium alters annexin 1 expression. Am J Pathol 158: 603-615. doi:10.1016/S0002-9440(10)64002-3. PubMed: 11159197.
16. Gil CD, La M, Perretti M, Oliani SM, (2006) Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int 30: 338-344. doi:10.1016/j.cellbi.2005.12.010. PubMed: 16530434.
17. Chatterjee BE, Yona S, Rosignoli G, Young RE, Nourshargh S, et al. (2005) Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. J Leukoc Biol 78: 639-646. doi:10.1189/jlb.0405206. PubMed: 16000391.
18. Perretti M, Croxtall JD, Wheller SK, Goulding NJ, Hannon R, et al. (1996) Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat Med 2: 1259-1262. doi:10.1038/nm1196-1259. PubMed: 8898757.
19. Damazo AS, Yona S, D'Acquisto F, Flower RJ, Oliani SM, et al. (2005) Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation. Am J Pathol 166: 1607-1617. doi:10.1016/S0002-9440(10)62471-6. PubMed: 15920146.
20. de Coupade C, Ajuebor MN, Russo-Marie F, Perretti M, Solito E, (2001) Cytokine modulation of liver annexin 1 expression during experimental endotoxemia. Am J Pathol 159: 1435-1443. doi:10.1016/S0002-9440(10)62530-8. PubMed: 11583971.
21. D'Amico M, Di Filippo C, La M, Solito E, McLean PG, et al. (2000) Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J 14: 1867-1869. PubMed: 11023969.
22. Gavins FN, Dalli J, Flower RJ, Granger DN, Perretti M, (2007) Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation. FASEB J 21: 1751-1758. doi:10.1096/fj.06-7842com. PubMed: 17317721.
23. Yang YH, Morand EF, Getting SJ, Paul-Clark M, Liu DL, et al. (2004) Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum 50: 976-984. doi:10.1002/art.20201. PubMed: 15022342.
24. Damazo AS, Yona S, Flower RJ, Perretti M, Oliani SM, (2006) Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol 176: 4410-4418. PubMed: 16547279.
25. Perretti M, D'Acquisto F, (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9: 62-70. doi:10.1038/nri2470. PubMed: 19104500.
26. D'Acquisto F, Perretti M, Flower RJ, (2008) Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. Br J Pharmacol 155: 152-169. PubMed: 18641677.
27. Babbin BA, Lee WY, Parkos CA, Winfree LM, Akyildiz A, et al. (2006) Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem 281: 19588-19599. doi:10.1074/jbc.M513025200. PubMed: 16675446.
28. Babbin BA, Laukoetter MG, Nava P, Koch S, Lee WY, et al. (2008) Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol 181: 5035-5044. PubMed: 18802107.
29. Martin GR, Perretti M, Flower RJ, Wallace JL, (2008) Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol 294: G764-G769. doi:10.1152/ajpgi.00531.2007. PubMed: 18202108.
30. Vong L, Ferraz JG, Dufton N, Panaccione R, Beck PL, et al. (2012) Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLOS ONE 7: e39244. doi:10.1371/journal.pone.0039244. PubMed: 22723974.
31. Sankaran S, George MD, Reay E, Guadalupe M, Flamm J, et al. (2008) Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol 82: 538-545. doi:10.1128/JVI.01449-07. PubMed: 17959677.
32. Sankaran S, Guadalupe M, Reay E, George MD, Flamm J, et al. (2005) Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A 102: 9860-9865. doi:10.1073/pnas.0503463102. PubMed: 15980151.
33. Verhoeven D, Sankaran S, Silvey M, Dandekar S, (2008) Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 82: 4016-4027. doi:10.1128/JVI.02164-07. PubMed: 18272585.
34. Leutenegger CM, Higgins J, Matthews TB, Tarantal AF, Luciw PA, et al. (2001) Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res Hum Retrovir 17: 243-251. doi:10.1089/088922201750063160. PubMed: 11177407.
35. Stallmach A, Hagel S, Bruns T, (2010) Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 24: 167-182. doi:10.1016/j.bpg.2010.01.002. PubMed: 20227030.
36. Kosicka A, Cunliffe AD, Mackenzie R, Gulrez Zariwala M, Perretti M, et al. (2012) Attenuation of plasma annexin A1 in human obesity. FASEB J, 27: 368-78. PubMed: 23038751.
37. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, et al. (1994) Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 106: 287-296. PubMed: 8299896.
38. Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, et al. (2010) A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 4: 221-256. doi:10.1016/j.crohns.2009.12.001. PubMed: 21122513.
39. Faria PC, Sena AA, Nascimento R, Carvalho WJ, Loyola AM, et al. (2010) Expression of annexin A1 mRNA in peripheral blood from oral squamous cell carcinoma patients. Oral Oncol 46: 25-30. doi:10.1016/j.oraloncology.2009.09.003. PubMed: 19833546.
40. Boxer LA, (2008) Role of neutrophils in genetic disorders of phagocyte function leading to IBD. J Pediatr Gastroenterol Nutr 46 (Suppl 1):: E17. doi:10.1097/01.mpg.0000313831.09089.36. PubMed: 18354321.
41. McCarthy DA, Rampton DS, Liu YC, (1991) Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86: 489-493. doi:10.1111/j.1365-2249.1991.tb02958.x. PubMed: 1684141.
42. Clarke K, Regueiro M, (2012) Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 18: 174-179. doi:10.1002/ibd.21792. PubMed: 21674731.
43. Stevens TR, Smith SF, Rampton DS, (1993) Antibodies to human recombinant lipocortin-I in inflammatory bowel disease. Clin Sci (Lond) 84: 381-386. PubMed: 8097682.
44. Beattie RM, Goulding NJ, Walker-Smith JA, MacDonald TT, (1995) Lipocortin-1 autoantibody concentration in children with inflammatory bowel disease. Aliment Pharmacol Ther 9: 541-545. PubMed: 8580275.
45. Vergnolle N, Pagès P, Guimbaud R, Chaussade S, Buéno L, et al. (2004) Annexin 1 is secreted in situ during ulcerative colitis in humans. Inflamm Bowel Dis 10: 584-592. doi:10.1097/00054725-200409000-00013. PubMed: 15472519.
46. D'Acquisto F, Paschalidis N, Sampaio AL, Merghani A, Flower RJ, et al. (2007) Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur J Immunol 37: 3131-3142. doi:10.1002/eji.200636792. PubMed: 17948261.
47. Caviglia R, Boskoski I, Cicala M, (2008) Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin Drug Saf 7: 617-632. doi:10.1517/14740338.7.5.617. PubMed: 18759714.
48. Sandborn WJ, (2008) Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135: 1442-1447. doi:10.1053/j.gastro.2008.09.053. PubMed: 18848556.
49. Gan H, Lee J, Ren F, Chen M, Kornfeld H, et al. (2008) Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence. Nat Immunol 9: 1189-1197. doi:10.1038/ni.1654. PubMed: 18794848.
50. Yona S, Heinsbroek SE, Peiser L, Gordon S, Perretti M, et al. (2006) Impaired phagocytic mechanism in annexin 1 null macrophages. Br J Pharmacol 148: 469-477. PubMed: 16633358.
51. D'Acquisto F, Merghani A, Lecona E, Rosignoli G, Raza K, et al. (2007) Annexin-1 modulates T-cell activation and differentiation. Blood 109: 1095-1102. PubMed: 17008549.
52. Beverley PC, (1992) Functional analysis of human T cell subsets defined by CD45 isoform expression. Semin Immunol 4: 35-41. PubMed: 1534262.
53. Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RA, et al. (1999) Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 42: 2166-2173. doi:10.1002/1529-0131(199910)42:10. PubMed: 10524689.